A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202;R-Roscovitine), administered twice daily for 7-days every 21 days.
De Bono, JS
MetadataShow full item record
Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Medicine Drug Development Unit (Kaye)
License start date
Br J Cancer. 2007, Jan 15, 1 (96), pp. 29 - 37